
G2B BioSolutions Denmark ApS

CVR-no.: 43237748

Hagens Alle 7
2900 Hellerup

Annual report
1 January 2023 - 31 December 2023

**The annual report has been presented and
approved on the company's general meeting
the**

10/04/2024

**Dayanand Jadhav
Chairman of general meeting**

Content

Company informations

Company informations

Reports

Statement by Management

Auditor's Reports

Report on an Engagement to Compile Financial Statements

Management's Review

Management's Review

Financial statement

Accounting Policies

Income statement

Balance sheet

Disclosures

Company information

**Reporting
company**

G2B BioSolutions Denmark ApS

Hagens Alle 7
2900 Hellerup

CVR-no.: 43237748

Reporting
period: 01/01/2023 - 31/12/2023**Auditor**CROWE STATS AUTORISERET REVISIONSINTERESSENTSKAB
Rygårds Allé 104
2900 Hellerup

Statement by Management

Management has today considered and approved the annual report for the financial year 01. January 2023 - 31. December 2023 for G2B BioSolutions Denmark ApS.

The annual report is presented in accordance with the Danish Financial Statements Act.

Management believes that the financial statements give a true and fair view of the company's assets, liabilities and financial position and of the result.

The annual report is submitted for approval by the General Assembly.

Management considers the conditions for opting out of audit to be met.

Hellerup, the 04/04/2024

Management

Dayanand Suryabhan Jadhav

Auditor's reports

To the shareholder of G2B BioSolutions Denmark ApS

We have compiled the financial statements of G2B BioSolutions Denmark ApS for the financial year 1. januar 2022 - 31. december 2022 based on the company's bookkeeping records and other information made available by enterprise.

The financial statements comprises a summary of significant accounting policies, income statement, balance sheet and notes.

We performed the engagement in accordance with ISRS 4410, Compilation Engagements.

We have applied our professional expertise to assist the enterprise in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We complied with the relevant provisions of the Danish Act on Approved Auditors and with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), including principles relating to integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are the enterprise's responsibility.

As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by enterprise for our compilation of the financial statements. Accordingly, we do not express an audit or a review conclusion on whether the financial statements have been prepared in accordance with the Danish Financial Statements Act.

Hellerup, the 04/04/2024

Crowe Statsautoriseret Revisionsinteressentskab v.m.b.a
CVR-no.: 33256879
Søren Jonassen, mne18488
Statsautoriseret revisor

Management's Review

Major Activities

The company has been without activities in the financial year.

Reasons for any major changes in your Company's activities or economy

The year's result in 2023 is DKK -10.098. The year's result is considered satisfactory.

Events after the end of the financial year (Optional)

After the end of the financial year, no events have occurred that could materially affect the company's financial position.

Accounting Policies

The annual report has been prepared in accordance with the regulation applying to Reporting class B.

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably. Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably. On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Balance sheet

Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.

Liabilities

Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.

Income statement 1 Jan 2023 - 31 Dec 2023

	Disclosure	2023 DKK	2022 DKK
Gross profit (loss)		-10,098	0
Profit (loss) from ordinary operating activities		-10,098	0
Sundry finance expenses		0	0
Profit (loss) from ordinary activities before tax		-10,098	0
Tax expense		0	0
Profit (loss)		-10,098	0
Proposed distribution of results			
Retained earnings		-10,098	0
Proposed distribution of profit (loss)		-10,098	0

Balance sheet 31 December 2023

Assets

	Disclosure	2023	2022
		DKK	DKK
Receivables from group enterprises		0	40,000
Receivables		0	40,000
Cash and cash equivalents		34,902	0
Current assets		34,902	40,000
TOTAL ASSETS		34,902	40,000

Balance sheet 31 December 2023

Liabilities and equity

	Disclosure	2023	2022
		DKK	DKK
Contributed capital		40,000	40,000
Retained earnings		-10,098	0
Total equity		29,902	40,000
Payables to vat and duties		5,000	0
Short-term liabilities other than provisions, gross		5,000	0
Liabilities other than provisions, gross		5,000	0
LIABILITIES AND EQUITY, GROSS		34,902	40,000

Disclosures

1. Disclosure of contingent liabilities

The company is jointly taxed with its parent company, Dayanad Jadhav Holding ApS (management company), and G2B BioSolutions ApS, and jointly and severally liable with other jointly taxed entities for payment of income taxes as well as for payment of withholding taxes on dividends which fall due for payment on.

The company has no other contingent liabilities.

2. Information on average number of employees

	2023
Average number of employees	1